Shockwave Medical, Inc. announced today that the company will be participating in two upcoming investor conferences.
SANTA CLARA, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in two upcoming investor conferences:
Shockwave Medical’s management team will participate in a fireside chat with analysts and investors at the upcoming 2023 Wells Fargo Healthcare Conference being held from September 6-8, 2023, in Boston, MA. The Shockwave Medical session is scheduled to take place Wednesday, September 6, 2023, at 1:30 p.m. Eastern Time.
Shockwave Medical’s management team is also scheduled to participate in in a fireside chat with analysts and investors at the upcoming 21st Annual Morgan Stanley Global Healthcare Conference being held from September 11-13, 2023, in New York, NY. The Shockwave Medical session is scheduled to take place Tuesday, September 12, 2023, at 2:15 p.m. Eastern Time.
Interested parties may access live and archived webcasts of the events on the “Investors” section of the company’s website at: https://ir.shockwavemedical.com.
About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.
Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com
Investor Contact:
Debbie Kaster
investors@shockwavemedical.com
